Craig W. Hendrix
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Craig W. Hendrix has a total of 629 co-authors. Here are the top co-authors by number of shared publications:
- Mark A. Marzinke
School of Medicine Johns Hopkins University Baltimore MD USA
18 shared publications - Rahul P. Bakshi
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
15 shared publications Edward J. Fuchs
Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
13 shared publications- Edward J. Fuchs
Department of Medicine (Clinical Pharmacology), Johns Hopkins University , Baltimore, Maryland
7 shared publications Mark A. Marzinke
Department of Pathology Johns Hopkins University School of Medicine Baltimore Maryland USA
6 shared publications- Max von Kleist
Project group 5 “Systems Medicine of Infectious Disease”, Robert Koch Institute, Berlin, Germany
6 shared publications
Latest Publications
- Open Access
Aging, HIV Status, and Sex Differentially Influence Antiretroviral Therapy Disposition Pathways in Rectosigmoid Tissue and Peripheral Blood Mononuclear Cells
People living with human immunodeficiency virus (HIV) are increasingly surviving into older age due to the effectiveness of antiretroviral (ARV) therapy (ART), creating a growing population in whom age-related changes may influence treatment outcomes. Although aging is known to affect drug disposition, the molecular mechanisms by which aging alters ARV pharmacology remain incompletely understood, particularly within tissue compartments, including the rectosigmoid region of the colon, that serve as sites of HIV transmission and persistence. To address this knowledge gap, we used proteomics by liquid chromatography-mass spectrometry (LC-MS) to evaluate the impact of age and HIV status on proteins and pathways relevant to ARV disposition in peripheral blood mononuclear cells (PBMC) and rectosigmoid colon tissue obtained from young (18-50) HIV-seronegative adults, older (65-80) HIV-seronegative adults, and older virally suppressed people living with HIV. We found that aging and HIV infection differentially influenced proteins predominantly within nucleos(t)ide reverse transcriptase inhibitor (NRTI) pathways, in rectosigmoid tissue and PBMC. HIV- associated effects to the proteome were more prominent in PBMC, whereas aging produced broader alterations in ARV disposition-related proteins in rectosigmoid tissue, including proteins involved in drug transport, intracellular drug activation, dephosphorylation, and nucleotide homeostasis. Several age-associated changes were further influenced by biologic sex, suggesting that aging may not affect ARV disposition uniformly across populations. To place these findings within a broader context, pathway analyses were performed that identified extensive tissue-specific remodeling associated with aging and HIV infection involving drug disposition, immune regulation, cellular metabolism, and disease-related pathways. Notably, aging was associated with alterations in pathways relevant to nucleotide metabolism and gastrointestinal tissue function, suggesting that processes beyond traditional drug transport and metabolism pathways may contribute to variability in ARV disposition with advancing age. Together, these findings identify aging as an important modifier of pathways that regulate ARV disposition within compartments relevant to HIV transmission and persistence. While the clinical consequences of our findings are unknown, these data provide a mechanistic foundation for future studies investigating whether age-associated changes influence the effectiveness of ART and HIV pre-exposure prophylaxis in older adults. Significance Statement: Adults over 50 years of age comprise a rapidly growing proportion of both HIV treatment and prevention populations, yet the biological effects of aging on antiretroviral drug disposition remain poorly understood. We demonstrate that aging, sex, and HIV status differentially alter proteins and pathways involved in antiretroviral transport, activation, and nucleotide homeostasis, with the most pronounced effects occurring in colorectal tissue, providing a mechanistic foundation for future studies of HIV therapeutics in aging populations. Visual
Open AccessAging, HIV Status, and Sex Differentially Influence Antiretroviral Therapy Disposition Pathways in Rectosigmoid Tissue and Peripheral Blood Mononuclear Cells
People living with human immunodeficiency virus (HIV) are increasingly surviving into older age due to the effectiveness of antiretroviral (ARV) therapy (ART), creating a growing population in whom age-related changes may influence treatment outcomes. Although aging is known to affect drug disposition, the molecular mechanisms by which aging alters ARV pharmacology remain incompletely understood, particularly within tissue compartments, including the rectosigmoid region of the colon, that serve as sites of HIV transmission and persistence. To address this knowledge gap, we used proteomics by liquid chromatography-mass spectrometry (LC-MS) to evaluate the impact of age and HIV status on proteins and pathways relevant to ARV disposition in peripheral blood mononuclear cells (PBMC) and rectosigmoid colon tissue obtained from young (18-50) HIV-seronegative adults, older (65-80) HIV-seronegative adults, and older virally suppressed people living with HIV. We found that aging and HIV infection differentially influenced proteins predominantly within nucleos(t)ide reverse transcriptase inhibitor (NRTI) pathways, in rectosigmoid tissue and PBMC. HIV- associated effects to the proteome were more prominent in PBMC, whereas aging produced broader alterations in ARV disposition-related proteins in rectosigmoid tissue, including proteins involved in drug transport, intracellular drug activation, dephosphorylation, and nucleotide homeostasis. Several age-associated changes were further influenced by biologic sex, suggesting that aging may not affect ARV disposition uniformly across populations. To place these findings within a broader context, pathway analyses were performed that identified extensive tissue-specific remodeling associated with aging and HIV infection involving drug disposition, immune regulation, cellular metabolism, and disease-related pathways. Notably, aging was associated with alterations in pathways relevant to nucleotide metabolism and gastrointestinal tissue function, suggesting that processes beyond traditional drug transport and metabolism pathways may contribute to variability in ARV disposition with advancing age. Together, these findings identify aging as an important modifier of pathways that regulate ARV disposition within compartments relevant to HIV transmission and persistence. While the clinical consequences of our findings are unknown, these data provide a mechanistic foundation for future studies investigating whether age-associated changes influence the effectiveness of ART and HIV pre-exposure prophylaxis in older adults. Significance Statement: Adults over 50 years of age comprise a rapidly growing proportion of both HIV treatment and prevention populations, yet the biological effects of aging on antiretroviral drug disposition remain poorly understood. We demonstrate that aging, sex, and HIV status differentially alter proteins and pathways involved in antiretroviral transport, activation, and nucleotide homeostasis, with the most pronounced effects occurring in colorectal tissue, providing a mechanistic foundation for future studies of HIV therapeutics in aging populations. Visual
- Open Access
- 3 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9) , e70278
Predicting Oral HIV Pre‐Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum
Cisgender women face an increased risk of HIV acquisition during pregnancy and postpartum. Oral pre‐exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (F/TDF) is recommended in pregnancy despite limited published pharmacokinetic (PK) and efficacy data during pregnancy. Altered PK during pregnancy may reduce prophylactic efficacy and necessitate higher adherence. Tenofovir alafenamide (TAF) is a newer tenofovir prodrug with higher tenofovir diphosphate (TFV‐DP) exposure in peripheral blood mononuclear cells (PBMCs), but the prophylactic efficacy of F/TAF across different reproductive stages in women is understudied. We adapted a multiscale modeling framework to predict the prophylactic efficacy of F/TDF and F/TAF across varying adherence levels and during the second trimester, third trimester, and 6–12 weeks postpartum. Clinical trial simulations were conducted utilizing PBMC TFV‐DP and emtricitabine triphosphate concentrations as surrogate markers for F/TAF and F/TDF efficacy. For both F/TDF and F/TAF, prophylactic efficacy was lowest during the second trimester, increased in the third trimester (but remained below nonpregnant levels), and was highest postpartum. At high adherence levels of five or more pills per week, predicted effectiveness remained high across pregnancy and postpartum and effectiveness exceeded 97% for both regimens, with maximum decreases in the second trimester of only 0.9 percent point for F/TDF and 0.3 percent point for F/TAF. These findings suggest that adherence is the primary determinant of PrEP effectiveness during pregnancy and postpartum, while pregnancy‐related PK changes have a limited impact on efficacy.
- 3 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9) , e70278
Open AccessPredicting Oral HIV Pre‐Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum
Cisgender women face an increased risk of HIV acquisition during pregnancy and postpartum. Oral pre‐exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (F/TDF) is recommended in pregnancy despite limited published pharmacokinetic (PK) and efficacy data during pregnancy. Altered PK during pregnancy may reduce prophylactic efficacy and necessitate higher adherence. Tenofovir alafenamide (TAF) is a newer tenofovir prodrug with higher tenofovir diphosphate (TFV‐DP) exposure in peripheral blood mononuclear cells (PBMCs), but the prophylactic efficacy of F/TAF across different reproductive stages in women is understudied. We adapted a multiscale modeling framework to predict the prophylactic efficacy of F/TDF and F/TAF across varying adherence levels and during the second trimester, third trimester, and 6–12 weeks postpartum. Clinical trial simulations were conducted utilizing PBMC TFV‐DP and emtricitabine triphosphate concentrations as surrogate markers for F/TAF and F/TDF efficacy. For both F/TDF and F/TAF, prophylactic efficacy was lowest during the second trimester, increased in the third trimester (but remained below nonpregnant levels), and was highest postpartum. At high adherence levels of five or more pills per week, predicted effectiveness remained high across pregnancy and postpartum and effectiveness exceeded 97% for both regimens, with maximum decreases in the second trimester of only 0.9 percent point for F/TDF and 0.3 percent point for F/TAF. These findings suggest that adherence is the primary determinant of PrEP effectiveness during pregnancy and postpartum, while pregnancy‐related PK changes have a limited impact on efficacy.
- Open Access
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men
- Open Access
- 10 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 4213
Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men
The human immunodeficiency virus (HIV) infected approximately 1.1 million individuals in 2024. There is no effective vaccine or cure, and funding cuts in resource-limited settings threaten treatment access. Cost-effective and widely available prevention strategies, such as oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP), are therefore essential. Current PrEP guidelines differ between cisgender women and men who have sex with men (MSM), based on mechanistic differences in tissue-level pharmacokinetics (PK) at vaginal vs. colorectal exposure sites. To test these mechanistic hypothesis, we use data from major FTC/TDF-PrEP trials to establish PrEP efficacy when used in MSM. We independently predict efficacy utilizing different PK-matrices in a mechanistic model, simulate each clinical trial informed by adherence data and compare the predictions with clinical efficacy estimates. With this combined approach, two of the five trials (HPTN 083, DISCOVER) yield sufficient statistical power to conclude that rectal tissue pharmacokinetics do not predict PrEP efficacy in MSM. In contrast, PBMC-based predictions agree with clinical PrEP efficacy and support the suitability of on-demand use of oral PrEP in MSM. When combining our findings with recent results on suitable pharmacokinetic markers in women, our work suggests that adherence requirements for cisgender women and MSM may not differ.
- 10 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 4213
Open AccessPharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men
The human immunodeficiency virus (HIV) infected approximately 1.1 million individuals in 2024. There is no effective vaccine or cure, and funding cuts in resource-limited settings threaten treatment access. Cost-effective and widely available prevention strategies, such as oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP), are therefore essential. Current PrEP guidelines differ between cisgender women and men who have sex with men (MSM), based on mechanistic differences in tissue-level pharmacokinetics (PK) at vaginal vs. colorectal exposure sites. To test these mechanistic hypothesis, we use data from major FTC/TDF-PrEP trials to establish PrEP efficacy when used in MSM. We independently predict efficacy utilizing different PK-matrices in a mechanistic model, simulate each clinical trial informed by adherence data and compare the predictions with clinical efficacy estimates. With this combined approach, two of the five trials (HPTN 083, DISCOVER) yield sufficient statistical power to conclude that rectal tissue pharmacokinetics do not predict PrEP efficacy in MSM. In contrast, PBMC-based predictions agree with clinical PrEP efficacy and support the suitability of on-demand use of oral PrEP in MSM. When combining our findings with recent results on suitable pharmacokinetic markers in women, our work suggests that adherence requirements for cisgender women and MSM may not differ.
- Open Access
- 5 May 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (5) , e0168025
Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathways
Oral tenofovir is a key antiretroviral used for treatment and pre-exposure prophylaxis (PrEP) of human immunodeficiency virus (HIV). A gel form has been tested for vaginal and rectal PrEP. We have shown that 7 days of tenofovir 1% gel had broad-ranging effects on gene expression in the rectum, especially suppression of anti-inflammatory mediators and induction of cell proliferation. Similarly, oral PrEP induced type I/III interferon-stimulated genes in the gut. It is unknown how long these effects last and whether they occur in other relevant body compartments. We measured the transcriptomes and proteomes of tissue samples obtained before and after daily topical tenofovir 1% gel application for 14 days (Microbicide Trials Network [MTN]-014 trial, rectal and vaginal) or 56 days (MTN-017 trial, rectal). While many changes seen after 7 days diminish after 14 and 56 days, some remain, notably increases in cell proliferation- and type I/III interferon-related genes. Vaginal gel uniquely induces changes related to epithelial-mesenchymal transition and angiogenesis. Induction of type I/III interferon-related genes is the most consistent and persistent mucosal response to tenofovir, occurring after both oral and topical use and at all tested time points. Hypothetically, interferon induction could improve antiviral efficacy, but also contribute to an increased chronic disease burden in people with HIV. IMPORTANCE: Analyzing gene expression data from three separate clinical trials, we find that the antiretroviral drug tenofovir, which belongs to the class of nucleotide analogue reverse transcriptase inhibitors, induces the type I/III interferon system of innate immunity in the mucosa. This effect occurs in the absence of HIV infection and manifests itself over various treatment durations and after both oral and topical drug delivery. Tenofovir and other related medications are important components of long-term antiretroviral treatment taken by people living with HIV. Therefore, this unexpected immunological effect might need to be considered as a potential contributor to comorbidities in people living with HIV, as well as an immunopharmacological co-factor when testing novel HIV cure interventions. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT01768962 , NCT01687218 , and NCT01232803 .
- 5 May 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (5) , e0168025
Open AccessMucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathways
Oral tenofovir is a key antiretroviral used for treatment and pre-exposure prophylaxis (PrEP) of human immunodeficiency virus (HIV). A gel form has been tested for vaginal and rectal PrEP. We have shown that 7 days of tenofovir 1% gel had broad-ranging effects on gene expression in the rectum, especially suppression of anti-inflammatory mediators and induction of cell proliferation. Similarly, oral PrEP induced type I/III interferon-stimulated genes in the gut. It is unknown how long these effects last and whether they occur in other relevant body compartments. We measured the transcriptomes and proteomes of tissue samples obtained before and after daily topical tenofovir 1% gel application for 14 days (Microbicide Trials Network [MTN]-014 trial, rectal and vaginal) or 56 days (MTN-017 trial, rectal). While many changes seen after 7 days diminish after 14 and 56 days, some remain, notably increases in cell proliferation- and type I/III interferon-related genes. Vaginal gel uniquely induces changes related to epithelial-mesenchymal transition and angiogenesis. Induction of type I/III interferon-related genes is the most consistent and persistent mucosal response to tenofovir, occurring after both oral and topical use and at all tested time points. Hypothetically, interferon induction could improve antiviral efficacy, but also contribute to an increased chronic disease burden in people with HIV. IMPORTANCE: Analyzing gene expression data from three separate clinical trials, we find that the antiretroviral drug tenofovir, which belongs to the class of nucleotide analogue reverse transcriptase inhibitors, induces the type I/III interferon system of innate immunity in the mucosa. This effect occurs in the absence of HIV infection and manifests itself over various treatment durations and after both oral and topical drug delivery. Tenofovir and other related medications are important components of long-term antiretroviral treatment taken by people living with HIV. Therefore, this unexpected immunological effect might need to be considered as a potential contributor to comorbidities in people living with HIV, as well as an immunopharmacological co-factor when testing novel HIV cure interventions. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT01768962 , NCT01687218 , and NCT01232803 .
- Open Access
- 12 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1599-1611
Evaluating “brain permeability”: A critical issue for the development of therapeutic agents for primary and metastatic brain tumors
Current assessments of brain permeability rely predominantly on drug delivery to contrast-enhancing tumor regions. However, substantial portions of central nervous system (CNS) tumors reside within non-enhancing brain (NEB), where drug concentrations frequently remain subtherapeutic. This collaborative Adult Brain Tumor Consortium and Food and Drug Administration workshop aimed to identify criteria for defining NEB permeability to accomplish two critical objectives: 1) allocate clinical trial resources toward agents achieving therapeutic NEB concentrations and 2) minimize systemic toxicity when CNS benefit is improbable. The workshop systematically evaluated permeability assessment modalities, including drug physicochemical properties, in vitro blood-brain barrier models, and penetration into cerebrospinal fluid and normal rodent brain. Methodological approaches to determine requisite NEB drug concentrations and approaches to measuring NEB pharmacokinetics and pharmacodynamics were examined. This culminated in developing the Non-Enhancing Brain Permeability Index (NEBPI), which assigns therapeutic agents to three categories: sufficiently permeable, insufficiently permeable, or impermeable. The NEBPI provides a standardized framework to assist investigators and regulatory agencies to evaluate NEB penetration before human efficacy studies are initiated for agents that require direct tumor contact. Assessing NEB drug penetration is critical to improving outcomes in CNS tumors and reducing the incidence of brain metastases in systemic malignancies.
- 12 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1599-1611
Open AccessEvaluating “brain permeability”: A critical issue for the development of therapeutic agents for primary and metastatic brain tumors
Current assessments of brain permeability rely predominantly on drug delivery to contrast-enhancing tumor regions. However, substantial portions of central nervous system (CNS) tumors reside within non-enhancing brain (NEB), where drug concentrations frequently remain subtherapeutic. This collaborative Adult Brain Tumor Consortium and Food and Drug Administration workshop aimed to identify criteria for defining NEB permeability to accomplish two critical objectives: 1) allocate clinical trial resources toward agents achieving therapeutic NEB concentrations and 2) minimize systemic toxicity when CNS benefit is improbable. The workshop systematically evaluated permeability assessment modalities, including drug physicochemical properties, in vitro blood-brain barrier models, and penetration into cerebrospinal fluid and normal rodent brain. Methodological approaches to determine requisite NEB drug concentrations and approaches to measuring NEB pharmacokinetics and pharmacodynamics were examined. This culminated in developing the Non-Enhancing Brain Permeability Index (NEBPI), which assigns therapeutic agents to three categories: sufficiently permeable, insufficiently permeable, or impermeable. The NEBPI provides a standardized framework to assist investigators and regulatory agencies to evaluate NEB penetration before human efficacy studies are initiated for agents that require direct tumor contact. Assessing NEB drug penetration is critical to improving outcomes in CNS tumors and reducing the incidence of brain metastases in systemic malignancies.
- Open Access
- 17 December 2025
- Published by Springer Nature in Research Square
Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in MSM
The human immunodeficiency virus (HIV) infected approximately 1.1 million individuals in 2024. Currently, there is no effective vaccine nor options to cure HIV. Moreover, resource-limited settings face massive cuts in funding for HIV treatment. To fight the global AIDS epidemic, cost-effective and widely-available HIV prevention, for example with oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP), are of utmost importance. Current PrEP guidelines differ between cisgender women and men who have sex with men (MSM). Mechanistically, the distinction is motivated by differences in tissue-level pharmacokinetics (PK) at vaginal vs. colo-rectal exposure sites. To test the validity of this mechanistic hypothesis, we utilized data from all major FTC/TDF-PrEP trials to establish 'PrEP efficacy when used' in MSM. We then independently predicted PrEP efficacy utilizing different PK-matrices (tissue vs. peripheral blood mononuclear cells, PBMCs) in a mechanistic model, simulated each clinical trial informed by adherence data and compared the predictions with clinical efficacy estimates to assess which pharmacological matrices predict efficacy. With this combined approach, two of the five trials (HPTN 083, DISCOVER) yielded sufficient statistical power to conclude (P<0.001) that pharmacokinetics in rectal tissue do not predict PrEP efficacy in MSM. In contrast, predictions utilizing drug concentrations in PBMCs agreed well with clinical PrEP efficacy and support previous findings regarding the suitability of on-demand use of oral PrEP in MSM. Moreover, when combining our findings with recent results on suitable pharmacokinetic markers in women, our work suggests that adherence requirements for cisgender women and MSM may not differ.
- 17 December 2025
- Published by Springer Nature in Research Square
Open AccessPharmacological markers of HIV prevention for oral pre-exposure prophylaxis in MSM
The human immunodeficiency virus (HIV) infected approximately 1.1 million individuals in 2024. Currently, there is no effective vaccine nor options to cure HIV. Moreover, resource-limited settings face massive cuts in funding for HIV treatment. To fight the global AIDS epidemic, cost-effective and widely-available HIV prevention, for example with oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP), are of utmost importance. Current PrEP guidelines differ between cisgender women and men who have sex with men (MSM). Mechanistically, the distinction is motivated by differences in tissue-level pharmacokinetics (PK) at vaginal vs. colo-rectal exposure sites. To test the validity of this mechanistic hypothesis, we utilized data from all major FTC/TDF-PrEP trials to establish 'PrEP efficacy when used' in MSM. We then independently predicted PrEP efficacy utilizing different PK-matrices (tissue vs. peripheral blood mononuclear cells, PBMCs) in a mechanistic model, simulated each clinical trial informed by adherence data and compared the predictions with clinical efficacy estimates to assess which pharmacological matrices predict efficacy. With this combined approach, two of the five trials (HPTN 083, DISCOVER) yielded sufficient statistical power to conclude (P<0.001) that pharmacokinetics in rectal tissue do not predict PrEP efficacy in MSM. In contrast, predictions utilizing drug concentrations in PBMCs agreed well with clinical PrEP efficacy and support previous findings regarding the suitability of on-demand use of oral PrEP in MSM. Moreover, when combining our findings with recent results on suitable pharmacokinetic markers in women, our work suggests that adherence requirements for cisgender women and MSM may not differ.
- Open Access
- 5 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e454-e461
Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083
Background: The HIV Prevention Trials Network (HPTN) 083 Trial demonstrated the superiority of long-acting, injectable cabotegravir (CAB) over daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis among cisgender men (MSM) and transgender women (TGW) who have sex with men. Plasma CAB concentrations associated with HIV protection in humans are unknown. Methods: We conducted a nested case-control study to investigate the association between plasma CAB concentrations and HIV risk. Plasma CAB concentrations were estimated for participants with confirmed HIV and for HIV-negative controls, who were matched on region, gender, and race. The window of HIV acquisition for cases was defined as the time between the last HIV-negative visit and the first HIV-positive visit; this window was used to evaluate CAB exposure for cases and their matched controls. Participants were categorized by the minimum estimated CAB concentration (CABmin) during this window relative to the protein-adjusted 90% CAB inhibitory concentration (1× PA-IC90) and 4× PA-IC90. HIV risk was modeled using conditional logistic regression. Results: Plasma CABmin was ≥4× PA-IC90 in 26% of HIV-positive cases, compared with 76% of matched controls. Plasma CABmin ≥4× PA-IC90 was associated with a 93% reduction in risk of HIV acquisition compared with CABmin <1× PA-IC90 (95% CI: 76%, 98%, P < .001). CABmin between 1× and 4× PA-IC90 had an estimated risk reduction of 79% compared with CABmin <1× PA-IC90 (95% CI: −19%, 96%, P = .07). Conclusions: Consistent plasma CAB concentrations ≥4× PA-IC90 were estimated to provide 93% protection against HIV in MSM and TGW.
- 5 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e454-e461
Open AccessEstimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083
Background: The HIV Prevention Trials Network (HPTN) 083 Trial demonstrated the superiority of long-acting, injectable cabotegravir (CAB) over daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis among cisgender men (MSM) and transgender women (TGW) who have sex with men. Plasma CAB concentrations associated with HIV protection in humans are unknown. Methods: We conducted a nested case-control study to investigate the association between plasma CAB concentrations and HIV risk. Plasma CAB concentrations were estimated for participants with confirmed HIV and for HIV-negative controls, who were matched on region, gender, and race. The window of HIV acquisition for cases was defined as the time between the last HIV-negative visit and the first HIV-positive visit; this window was used to evaluate CAB exposure for cases and their matched controls. Participants were categorized by the minimum estimated CAB concentration (CABmin) during this window relative to the protein-adjusted 90% CAB inhibitory concentration (1× PA-IC90) and 4× PA-IC90. HIV risk was modeled using conditional logistic regression. Results: Plasma CABmin was ≥4× PA-IC90 in 26% of HIV-positive cases, compared with 76% of matched controls. Plasma CABmin ≥4× PA-IC90 was associated with a 93% reduction in risk of HIV acquisition compared with CABmin <1× PA-IC90 (95% CI: 76%, 98%, P < .001). CABmin between 1× and 4× PA-IC90 had an estimated risk reduction of 79% compared with CABmin <1× PA-IC90 (95% CI: −19%, 96%, P = .07). Conclusions: Consistent plasma CAB concentrations ≥4× PA-IC90 were estimated to provide 93% protection against HIV in MSM and TGW.
- Open Access
- 31 October 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (11) , e70056
Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084
Introduction: HPTN 084 found that long‐acting cabotegravir (CAB‐LA) was well‐tolerated and significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (F/TDF). During the blinded phase of the trial, participants were required to use an effective method of contraception, including an injectable or implantable hormonal contraceptive (HC) agent. A contraceptive sub‐study assessed the pharmacokinetic interactions between pre‐exposure prophylaxis agents (CAB‐LA or F/TDF) and etonogestrel (ENG), medroxyprogesterone acetate (MPA) or norethindrone enanthate (NET‐EN). Methods: Participants were enrolled in a nested sub‐study between 24 February 2020 and 26 October 2020. Via a convenience sampling strategy, plasma concentrations of ENG, MPA and NET‐EN were evaluated at enrolment and weeks 25, 49 and 73; plasma tenofovir (TFV) and CAB concentrations were determined at contemporaneous visits. Participants were allowed to switch contraceptives, and HC assessments were adjusted accordingly. Geometric mean concentrations were calculated and compared using t ‐tests or Fisher's exact tests. Results: One hundred and seventy participants were included in this analysis. Hormone concentrations at all study visits were comparable between the CAB‐LA and F/TDF study arms. Among participants randomized to the CAB‐LA arm, geometric mean concentrations declined from enrolment to the follow‐up period for ENG (335 to 202 pg/ml), MPA (1520 to 1138 pg/ml) and NET‐EN (3715 to 1888 pg/ml); similar findings were observed among participants randomized to the F/TDF arm. Observed HC declines are likely attributed to the timing of contraceptive administration relative to sampling; the percentage of participants with hormone concentrations above thresholds associated with ovulation suppression was high (73−100%) and did not differ between arms. CAB concentrations were comparable across contraceptive types, with 97.8−98.1% of participants yielding trough CAB concentrations above the protocol‐specified target threshold. TFV concentrations were unquantifiable for most participants, irrespective of contraceptive agent, rendering comparisons largely uninformative. Conclusions: Given the comparable hormone concentrations between arms and the likely influence of the timing of sample collection on observed measurements, clinically significant interactions between CAB‐LA and HC are not expected. Associations between F/TDF and hormone concentrations could not be effectively evaluated due to low adherence to F/TDF. Clinical Trial Registration: NCT0316456
- 31 October 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (11) , e70056
Open AccessEvaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084
Introduction: HPTN 084 found that long‐acting cabotegravir (CAB‐LA) was well‐tolerated and significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (F/TDF). During the blinded phase of the trial, participants were required to use an effective method of contraception, including an injectable or implantable hormonal contraceptive (HC) agent. A contraceptive sub‐study assessed the pharmacokinetic interactions between pre‐exposure prophylaxis agents (CAB‐LA or F/TDF) and etonogestrel (ENG), medroxyprogesterone acetate (MPA) or norethindrone enanthate (NET‐EN). Methods: Participants were enrolled in a nested sub‐study between 24 February 2020 and 26 October 2020. Via a convenience sampling strategy, plasma concentrations of ENG, MPA and NET‐EN were evaluated at enrolment and weeks 25, 49 and 73; plasma tenofovir (TFV) and CAB concentrations were determined at contemporaneous visits. Participants were allowed to switch contraceptives, and HC assessments were adjusted accordingly. Geometric mean concentrations were calculated and compared using t ‐tests or Fisher's exact tests. Results: One hundred and seventy participants were included in this analysis. Hormone concentrations at all study visits were comparable between the CAB‐LA and F/TDF study arms. Among participants randomized to the CAB‐LA arm, geometric mean concentrations declined from enrolment to the follow‐up period for ENG (335 to 202 pg/ml), MPA (1520 to 1138 pg/ml) and NET‐EN (3715 to 1888 pg/ml); similar findings were observed among participants randomized to the F/TDF arm. Observed HC declines are likely attributed to the timing of contraceptive administration relative to sampling; the percentage of participants with hormone concentrations above thresholds associated with ovulation suppression was high (73−100%) and did not differ between arms. CAB concentrations were comparable across contraceptive types, with 97.8−98.1% of participants yielding trough CAB concentrations above the protocol‐specified target threshold. TFV concentrations were unquantifiable for most participants, irrespective of contraceptive agent, rendering comparisons largely uninformative. Conclusions: Given the comparable hormone concentrations between arms and the likely influence of the timing of sample collection on observed measurements, clinically significant interactions between CAB‐LA and HC are not expected. Associations between F/TDF and hormone concentrations could not be effectively evaluated due to low adherence to F/TDF. Clinical Trial Registration: NCT0316456
- 28 June 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (4) , 826-834
Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex With Men: The DREAM ATN Study (ATN 163)
Background: Young men who have sex with men (YMSM) are disproportionately affected by human immunodeficiency virus (HIV); however, use of oral preexposure prophylaxis (PrEP) remains suboptimal. This study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of a novel tenofovir (TFV) rectal microbicide douche for HIV prevention. Methods: Eight HIV-negative YMSM (aged 18–24 years) participated in a single-dose, open-label trial. Each received 660 mg of TFV in a 125-mL rectal douche. Safety was assessed via clinical monitoring and adverse event (AE) reporting. PK analysis measured TFV and TFV-diphosphate (TFV-DP) concentrations in blood and rectal tissue. PD was evaluated using ex vivo HIV-1 challenge assays in rectal biopsies. Results: No serious AEs occurred. Five mild to moderate AEs (eg, nausea, hyperglycemia) were reported, none related to the product. Median peak plasma TFV concentration (14.5 ng/mL) remained below levels seen with oral TDF. Median peak (24-hour) rectal tissue cell TFV-DP concentrations were 8319 fmol/106 cells with a corresponding 0.9 log10 HIV-1 p24 antigen reduction observed in ex vivo challenge assays. Rectal tissue TFV-DP concentrations exceeded those associated with on-demand oral 2-1-1 dosing from 1 to 72 hours and suppressed HIV-1 p24 antigen production in colonic explants. Acceptability was high: 87.5% reported satisfaction, and 75% would consider future use. Conclusions: The TFV rectal douche was safe, well tolerated, and acceptable to YMSM. Its favorable PK and PD profiles support further investigation as a behaviorally congruent, on-demand PrEP strategy. Additional studies are needed to assess long-term safety and efficacy in larger, more diverse populations. Clinical Trials Registration: NCT04686279.
- 28 June 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (4) , 826-834
Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex With Men: The DREAM ATN Study (ATN 163)
Background: Young men who have sex with men (YMSM) are disproportionately affected by human immunodeficiency virus (HIV); however, use of oral preexposure prophylaxis (PrEP) remains suboptimal. This study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of a novel tenofovir (TFV) rectal microbicide douche for HIV prevention. Methods: Eight HIV-negative YMSM (aged 18–24 years) participated in a single-dose, open-label trial. Each received 660 mg of TFV in a 125-mL rectal douche. Safety was assessed via clinical monitoring and adverse event (AE) reporting. PK analysis measured TFV and TFV-diphosphate (TFV-DP) concentrations in blood and rectal tissue. PD was evaluated using ex vivo HIV-1 challenge assays in rectal biopsies. Results: No serious AEs occurred. Five mild to moderate AEs (eg, nausea, hyperglycemia) were reported, none related to the product. Median peak plasma TFV concentration (14.5 ng/mL) remained below levels seen with oral TDF. Median peak (24-hour) rectal tissue cell TFV-DP concentrations were 8319 fmol/106 cells with a corresponding 0.9 log10 HIV-1 p24 antigen reduction observed in ex vivo challenge assays. Rectal tissue TFV-DP concentrations exceeded those associated with on-demand oral 2-1-1 dosing from 1 to 72 hours and suppressed HIV-1 p24 antigen production in colonic explants. Acceptability was high: 87.5% reported satisfaction, and 75% would consider future use. Conclusions: The TFV rectal douche was safe, well tolerated, and acceptable to YMSM. Its favorable PK and PD profiles support further investigation as a behaviorally congruent, on-demand PrEP strategy. Additional studies are needed to assess long-term safety and efficacy in larger, more diverse populations. Clinical Trials Registration: NCT04686279.